We are monitoring the impact of COVID-19 on Europe Lung Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 835
Share on
Share on

Europe Lung Cancer Therapeutics Market Research Report - Segmented By Treatment Type & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends and Forecast (2019 - 2024)

Pulished: February, 2020
ID: 835
Pages: 145

Europe Lung Cancer Therapeutics Market Size & Growth (2019 - 2024)

The Europe Lung Cancer Therapeutics Market was worth USD 1.67 billion in 2019 and estimated to be growing at a CAGR of 6.47%, to reach USD 2.29 billion by 2024. Europe is the second-largest region for the lung cancer therapeutics market.

Lung cancer is the foremost cause of cancer deaths in the European region, and the prevalence of lung cancer is cumulative significantly. It is the common cause of mortality and illness not only in developed countries but also in developing countries. Smoking is thought of as the main cause of lung cancer, though lung cancer also follows in non-smokers.

Growth in the lung cancer therapeutics market is projected on account of growing prevalence rate, constant contact to radiation and carcinogens and increasing patient alertness.

Furthermore, the late advent of disease symptoms leads to postponement in diagnosis and progression in the cancer stage, which results in the rising cost of the treatment, and thus makes higher revenues for the Europe treatment market.

This research report segmented and sub-segmented into the following categories:

  • By Treatment Type: Chemotherapy (Cisplatin, Taxol, Navelbine, Camptosar and Alimta), Radiotherapy (External Beam, Internal Beam and Systemic) and Other Drugs (Abraxane, Avastin, Crizotinib, Docetaxel and Gefitinib)
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe

Regionally, U.K is the leading market due to a high population base suffering from lung cancer while Germany is anticipated to witness high growth in the forecast period.

Key players operating in the Europe Lung Cancer Therapeutics Market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstraZeneca plc, and Sanofi-Aventis.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                

5. Market Segmentation                                                              

                5.1 By Treatment Type                                 

                                5.1.1 Chemotherapy                     

                                                5.1.1.1 Cisplatin

                                                5.1.1.2 Taxol      

                                                5.1.1.3 Navelbine            

                                                5.1.1.4 Camptosar          

                                                5.1.1.5 Alimta   

                                5.1.2 Radiotherapy                         

                                                5.1.2.1 External Beam   

                                                5.1.2.2 Internal Beam    

                                                5.1.2.3 Systemic              

                                5.1.3 Other Drugs                            

                                                5.1.3.1 Abraxane             

                                                5.1.3.2 Avastin 

                                                5.1.3.3 Crizotinib             

                                                5.1.3.4 Docetaxel            

                                                5.1.3.5 Gefitinib               

6. Geographical Analysis                                                              

                6.1 Introduction                                              

                6.2 U.K                                

                6.3 Spain                                             

                6.4 Germany                                     

                6.5 Italy                                               

                6.6 France                                          

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

8. Market Leaders' Analysis                                                        

                8.1 BoehringerIngelheim GmbH                               

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Hoffman-La Roche                                  

                8.3 Pfizer Inc.                                    

                8.4 GlaxoSmitKline                                         

                8.5 Eli Lilly and Company                                             

                8.6 AstrazenecaPlc                                         

                8.7 Sanofi-Aventis                                          

                8.8 Agennix AG                                

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

10. Expert Opinions                                                        

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Lung Cancer Therapeutics Market By Region, From 2019-2024 (USD Billion)
  2. Europe Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  3. Europe Chemotherapy Market By Region, From 2019-2024 (USD Billion)
  4. Europe Radiotherapy Market By Region, From 2019-2024 (USD Billion)
  5. Europe Other Lung Cancer Therapeutic Drugs Market By Region, From 2019-2024 (USD Billion)
  6. U.K Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  7. Spain Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  8. Germany Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  9. Italy Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  10. France Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  11. Europe Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  12. Europe Cisplatin Market By Region, From 2019-2024 (USD Billion)
  13. Europe Taxol Market By Region, From 2019-2024 (USD Billion)
  14. Europe Navelbine Market By Region, From 2019-2024 (USD Billion)
  15. Europe Camptosar Market By Region, From 2019-2024 (USD Billion)
  16. Europe Alimta Market By Region, From 2019-2024 (USD Billion)
  17. U.K Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  18. Spain Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  19. Germany Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  20. Italy Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  21. France Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  22. Europe Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  23. Europe External Beam Market By Region, From 2019-2024 (USD Billion)
  24. Europe Internal Beam Market By Region, From 2019-2024 (USD Billion)
  25. Europe Systemic Market By Region, From 2019-2024 (USD Billion)
  26. U.K Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  27. Spain Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  28. Germany Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  29. Italy Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  30. France Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  31. Europe Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  32. Europe Abraxane Market By Region, From 2019-2024 (USD Billion)
  33. Europe Avastin Market By Region, From 2019-2024 (USD Billion)
  34. Europe Crizotinib Market By Region, From 2019-2024 (USD Billion)
  35. Europe Docetaxel Market By Region, From 2019-2024 (USD Billion)
  36. Europe Gefitinib Market By Region, From 2019-2024 (USD Billion)
  37. U.K Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  38. Spain Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  39. Germany Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  40. Italy Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  41. France Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample